Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib in Metastatic Triple-Negative Breast Cancer
NCT02362230Phase 2Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2015
- Primary completion
- Dec 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of icotinib in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen University. Started Jan 2015; status: terminated.
02
Drugs
icotinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02362230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02362230.